Effects of various inhibitors and hypothermia on uptake of ONO-1301, and effects of ONO-1301 on the uptake of TCA and pravastatin by isolated rat hepatocytes3-a
| Uptake | ||
|---|---|---|
| Na+-dependent (%)3-a | Na+-independent (%)3-a | |
| ONO-1301 uptake | ||
| Control | 100 | 100 |
| O°C | 1.2 ± 1.2***3-b | 5.0 ± 1.6***3-b |
| Rotenone, 30 μM | 51.5 ± 17.2 | 47.4 ± 1.8***3-b |
| FCCP, 2 μM | 82.2 ± 27.9 | 34.3 ± 2.2***3-b |
| ONO-1301 500 μM | 13.4 ± 7.2***3-b | 4.0 ± 1.4***3-b |
| TCA, 20 μM | 64.2 ± 17.7*3-b | 78.4 ± 3.2 |
| TCA, 50 μM | 109.4 ± 65.7 | 53.1 ± 5.6***3-b |
| TCA, 100 μM | 71.4 ± 18.9 | 50.0 ± 2.7***3-b |
| TCA, 500 μM | 23.4 ± 11.8***3-b | 44.3 ± 3.9***3-b |
| Pravastatin, 20 μM | 33.9 ± 14.2**3-b | 95.1 ± 4.9 |
| Pravastatin, 50 μM | 51.3 ± 15.7*3-b | 74.1 ± 3.1*3-b |
| Pravastatin, 100 μM | 44.4 ± 20.6**3-b | 67.6 ± 2.6**3-b |
| Pravastatin, 500 μM | 49.4 ± 19.4*3-b | 45.5 ± 2.8***3-b |
| Pravastatin uptake | ||
| Control | 100 | |
| Pravastatin, 500 μM | 16.8 ± 1.1***3-b | |
| ONO-1301, 1 μM | 87.1 ± 4.1 | |
| ONO-1301, 10 μM | 40.3 ± 3.1***3-b | |
| ONO-1301, 100 μM | 6.5 ± 1.1***3-b | |
| ONO-1301, 500 μM | 4.6 ± 2.0***3-b | |
| TCA uptake | ||
| Control | 100 | 100 |
| TCA, 500 μM | 4.3 ± 0.6***3-b | 6.9 ± 3.3***3-b |
| ONO-1301, 1 μM | 90.2 ± 4.0 | 95.6 ± 13.5 |
| ONO-1301, 10 μM | 44.7 ± 3.5*3-b | 60.4 ± 6.1*3-b |
| ONO-1301, 100 μM | 9.2 ± 1.8***3-b | 28.8 ± 5.2***3-b |
| ONO-1301, 500 μM | 2.5 ± 0.7***3-b | 19.2 ± 3.3***3-b |